Responses
Clinical/translational cancer immunotherapy
Original research
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Compose a Response to This Article
Other responses
No responses have been published for this article.